Benaroya Research Institute

The trials here

What the 14 trials at this site are about, from their registry records.

Conditions

• Type 1 diabetes14 trials
• Type 2 diabetes2 trials

Phase

• Phase 25 trials
• Early phase 12 trials
• Phase 11 trial
• Phase 1/21 trial

Status

• Recruiting7 trials
• Completed3 trials
• Active, not recruiting2 trials
• Not yet recruiting1 trial
• Terminated1 trial

Lead sponsor

• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)6 trials
• Milton S. Hershey Medical Center2 trials
• Benaroya Research Institute1 trial
• COUR Pharmaceutical Development Company, Inc.1 trial
• National Institute of Allergy and Infectious Diseases (NIAID)1 trial
• and 3 more

Running trials

• Recruiting

  Platform Trial to Delay Stage 3 Diabetes: Comparing Teplizumab With ATG

  NCT07216391· Phase 2· National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)· Source

  Contact: Arlene Colmenares

• Recruiting

  Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus

  NCT07142252· Phase 2· National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)· Source

  Contact: Megan Olson

• Recruiting

  CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)

  NCT06783309· Phase 1/2· COUR Pharmaceutical Development Company, Inc.· Source

  Contact: Erica Bourget

• Recruiting

  Diabetes RElated to Acute Pancreatitis and Its Mechanisms: Metabolic Outcomes Using Novel CGM Metrics

  NCT06401577· Milton S. Hershey Medical Center· Source

  Contact: Kim Varner

• Active, not recruiting

  Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes

  NCT03929601· Phase 2· National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)· Source

• Active, not recruiting

  Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)

  NCT05743244· Phase 2· National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)· Source

• Recruiting

  Diabetes RElated to Acute Pancreatitis and Its Mechanisms

  NCT05197920· Milton S. Hershey Medical Center· Source

  Contact: Kim Varner

• Recruiting

  EXtremely Early-onset Type 1 Diabetes EXtremely Early-onset Type 1 Diabetes (A Musketeers' Memorandum Study)

  NCT03369821· University of Exeter· Source

  Contact: Cate Speake

• Recruiting

  Type 1 Diabetes Extension Study

  NCT02734277· National Institute of Allergy and Infectious Diseases (NIAID)· Source

  Contact: Katie Bennett

• Recruiting

  TrialNet Pathway to Prevention of T1D

  NCT00097292· University of South Florida· Source

  Contact: Katie Bennett

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Type 1 diabetes8 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Terminated

  STOP-T1D Low-Dose (ATG)

  NCT04291703· Phase 2· National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)· Source

• Completed

  Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D

  NCT05281614· Early phase 1· Benaroya Research Institute· Source

• Completed

  Early Markers of Disease and Response to Therapy

  NCT04118153· Early phase 1· Sandra Lord, MD· Source

• Completed

  A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041

  NCT04279613· Phase 1· National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)· Source